TEST:

SOPHiA DDM Dx RNAtarget Oncology Solution

"SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a significant new collaboration with Jessa Ziekenhuis in Hasselt, Belgium. The institutions will partner to bring cutting edge genomic testing and oncology research to cancer patients across Belgium...Through this collaboration, the hospital will adopt SOPHiA DDM™ across its pathology operations to unify its next-generation sequencing (NGS) workflows under a single platform. "

"SOPHiA GENETICS...announced from the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications...Powered by the Company’s proprietary deep learning algorithms, the SOPHiA DDM™ Platform supports state-of-art oncology technologies, including five CE-IVD SOPHiA DDM applications, including the newly registered SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution and SOPHiA DDM™ Dx RNAtarget Oncology Solution."